Windward prices $175M IPO to advance China-licensed lung drugs

BioPharma DiveView source article

Part of story

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 20262 sourcesBiotechnology Asthma Respiratory diseases Pharmaceutical Industry Drug development Clinical trials Biotech innovation COPD

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Other sources for this story

Reuters

Windward prices $175M IPO to advance China-licensed lung drugs

Part of story

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Other sources for this story

Novo Holdings-backed Windward Bio raises $175 million in US IPO | Reuters

Windward prices $175M IPO to advance China-licensed lung drugs

Part of story

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Other sources for this story

Novo Holdings-backed Windward Bio raises $175 million in US IPO | Reuters